RSV shot linked to a dramatic decline in babies falling seriously ill with virus

The survey published this Friday, May 2, in "The Lancet Child & Adolescent Health" reveals that nirsevimab, the molecule of this treatment, reduces the risk of hospitalisation due to bronchiolite in children 12 months of age and younger by 83% on average.

RSV shot linked to a dramatic decline in babies falling seriously ill with virus

A single-shot therapy offered to newborns in Ireland between September last and the end of February has dramatically reduced the number of infants facing a potentially deadly virus.

Timing of RSV Immunization Matters for Infant Protection

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring its effectiveness, according to Yale research published in ...

The Ministry of Health of the Nation began the distribution of Palivizumab to all jurisdictions of the country. This monoclonal antibody allows to prevent severe low respiratory infection by respiratory syncicial virus (SRV) and associated infant morbidity and mortality, in children born up to 32 weeks of gestational age or weighing up to 1,500 g. and in those with severe congenital heart disease. The delivery to the jurisdictions was organized …

FDA approves first vaccine for respiratory syncytial virus

On May 3, the Food and Drug Administration (FDA) approved the first vaccine — Arexvy — for respiratory syncytial virus (RSV) to lower respiratory tract disease in people older than 60 years. This is the first RSV vaccine to be approved anywhere in the world.  The vaccine is manufactured by the company, GSK, and the … Continue reading FDA approves first vaccine for respiratory syncytial virus

According to a new study, the vaccination of newborn babies against the RS virus is very effective. Immunised babies often suffer less severely.